The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus
Abstract
The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother‐to‐infant hepatitis B virus (HBV) transmissions is not clearly understood. We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)– and hepatitis B e antigen–positive pregnant women with HBV DNA ≥7.5 log 10 IU/mL. The mothers received no medication (control group, n = 56, HBV DNA 8.22 ± 0.39 log 10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 ± 0.47 log 10 IU/mL) from 30‐32 weeks of gestation until 1 month postpartum. Primary outcome was infant HBsAg at 6 months old. At delivery, the TDF group had lower maternal HBV DNA levels (4.29 ± 0.93 versus 8.10 ± 0.56 log 10 IU/mL, P < 0.0001). Of the 121/123 newborns, the TDF group had lower rates of HBV DNA positivity at birth (6.15% versus 31.48%, P = 0.0003) and HBsAg positivity at 6 months old (1.54% versus 10.71%, P = 0.0481). Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434) and amniocentesis was associated with higher risk (odds ratio 6.82, P = 0.0220) of infant HBsAg positivity. The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times the upper limit of normal for ≥3 months (3.23% versus 14.29%, P = 0.0455), a lesser extent of postpartum elevations of ALT ( P = 0.007), and a lower rate of ALT over five times the upper limit of normal (1.64% versus 14.29%, P = 0.0135) at 2 months postpartum. Maternal creatinine and creatinine kinase levels, rates of congenital anomaly, premature birth, and growth parameters in infants were comparable in both groups. At 12 months, one TDF‐group child newly developed HBsAg positivity, presumably due to postnatal infection and inefficient humoral responses to vaccines. Conclusions : Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and infant HBsAg positivity at 6 months and ameliorated maternal ALT elevations. (H epatology 2015;62:375–386
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vertical Transmission of Hepatitis B Antigen in Taiwan
Stevens, C. E., Beasley, R. P., Tsui, J., & Lee, W.-C. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504102921503 · Cited by 1,022
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lee, C.-M., Lin, S.-M., Chu, H.-C., Wu, T.-C., Yang, S.-S., Kuo, H.-S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 635
Self-citationThree-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Xu, W. ‐., Cui, Y. ‐., Wang, L., Yang, H., Liang, Z. ‐., Li, X. ‐., Zhang, S. ‐., Qiao, F. ‐., Campbell, F., Chang, C. ‐., et al. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01056.x · Cited by 387
Self-citationPerinatal transmission of hepatitis B virus: an Australian experience
Wiseman, E., Fraser, M. A., Holden, S., Glass, A., Kidson, B. L., Heron, L. G., Maley, M. W., Ayres, A., LOCARNINI, S. A., & Levy, M. T. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02524.x · Cited by 378
Han, G.-R., Cao, M.-K., Zhao, W., Jiang, H.-X., Wang, C.-M., Bai, S.-F., Yue, X., Wang, G.-J., Tang, X., & Fang, Z.-X. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.032 · Cited by 363
Ni, Y., Huang, L., Chang, M., Yen, C., Lu, C., You, S., Kao, J., Lin, Y., Chen, H., Hsu, H., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.055 · Cited by 348
Self-citationBeasley, P. R., Hwang, L.-Y., Stevens, C. E., Lin, C.-C., Hsieh, F.-J., Wang, K.-Y., Sun, T.-S., & Szmuness, W. (1983) · Hepatology · doi:10.1002/hep.1840030201 · Cited by 290
van Zonneveld, M., van Nunen, A. B., Niesters, H. G. M., de Man, R. A., Schalm, S. W., & Janssen, H. L. A. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00440.x · Cited by 289
Wen, W.-H., Chang, M.-H., Zhao, L.-L., Ni, Y.-H., Hsu, H.-Y., Wu, J.-F., Chen, P.-J., Chen, D.-S., & Chen, H.-L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.015 · Cited by 267
Self-citation
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationApproved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., Zhang, H., Zou, H., Zhu, B., Zhao, W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508660 · Cited by 573
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
Jourdain, G., Ngo-Giang-Huong, N., Harrison, L., Decker, L., Khamduang, W., Tierney, C., Salvadori, N., Cressey, T. R., Sirirungsi, W., Achalapong, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708131 · Cited by 285
Metadata
- Authors
- Chen, H., Lee, C., Chang, C., Ni, Y., Shyu, M., Chen, S., Hu, J., Lin, H. H., Zhao, L., Mu, S., Lai, M., Lee, C., Lin, H., Tsai, M., Hsu, J., Chen, D., Chan, K. A., Chang, M., & Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study)
- Venue
- Hepatology
- Published
- 2015-05-13
- Volume
- 62
- Issue
- 2
- Pages
- 375-386
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2054581016
- Cited by
- 255
- References
- 29
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus. https://app.cochat.ai/papers/10.1002/hep.27837
- The paper
- Chen, H., Lee, C., Chang, C., Ni, Y., Shyu, M., Chen, S., Hu, J., Lin, H. H., Zhao, L., Mu, S., Lai, M., Lee, C., Lin, H., Tsai, M., Hsu, J., Chen, D., Chan, K. A., Chang, M., & Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study). (2015). Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus. Hepatology. https://doi.org/10.1002/hep.27837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
